Issues encountered in recent attempts to develop novel antidepressant agents

Annals of the New York Academy of Sciences

Volumn 1345, Issue 1, 2015, Pages 67-73

  Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Glutamate; Ketamine; Major depression; Onabotulinumtoxin

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; BOTULINUM TOXIN A; GLUCOCORTICOID ANTAGONIST; KETAMINE; MELATONIN RECEPTOR AGONIST; SEROTONIN 2 ANTAGONIST; VILAZODONE; VORTIOXETINE; BENZOFURAN DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SULFIDE;

ARTICLE; BRAIN DEPTH STIMULATION; DRUG EFFECT; DRUG SYNTHESIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NERVE CELL NETWORK; NEUROENDOCRINE SYSTEM; PLACEBO EFFECT; SYNAPSE; TRANSCRANIAL MAGNETIC STIMULATION; DEPRESSIVE DISORDER; DRUG DEVELOPMENT; ISOLATION AND PURIFICATION; NEUROSECRETION; PHYSIOLOGY; PROCEDURES;

ANTIDEPRESSIVE AGENTS; BENZOFURANS; DEEP BRAIN STIMULATION; DEPRESSIVE DISORDER; DRUG DISCOVERY; HUMANS; INDOLES; KETAMINE; NERVE NET; NEUROSECRETORY SYSTEMS; PIPERAZINES; PLACEBO EFFECT; SULFIDES; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84943378191     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12716     Document Type: Article

References (44)

1. Papakostas, G.I. & M. Fava . 2009. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur. Neuropsychopharm. 19: 34-40.
2. Walsh, B.T., S.N. Seidman, R. Sysko, et al. 2002. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840-1847.
3. Laughren, T.P., J. Gobburu, R.J. Temple, et al. 2011. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J. Clin. Psychiatry 72: 1166-1173.
4. Katona, C., T. Hansen & C.K. Olsen . 2012. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int. Clin. Psychopharmacol. 27: 215-223.
5. McIntyre, R.S., S. Lophaven & C.K. Olsen . 2014. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol. 17: 1557-1567.
6. Raskin, J., C.G. Wiltse, A. Siegal, et al. 2007. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 164: 900-909.
7. Shire Reports Top-line Results from Two Phase 3 Studies for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) as an Adjunctive Treatment for Adults with Major Depressive Disorder. Press Release, February 6, 2014.
8. Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clincial Studies as Add-On Therapy for Major Depressive Disorder, Lilly. Cited December 5, 2013. http://investor.lilly.com/releasedetail.cfm?ReleaseID=811751.
9. Berman, R.M., A. Cappiello, A. Anand, et al. 2000. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47: 351-354.
10. Zarate, C.A., Jr., J.B. Singh, P.J. Carlson, et al. 2006. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63: 856-864.
11. Murrough, J.W., D.V. Iosifescu, L.C. Chang, et al. 2013. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry 170: 1134-1142.
12. Luckenbaugh, D.A., M.J. Niciu, D.F. Ionescu, et al. 2014. Do the dissociative side effects of ketamine mediate its antidepressant effects? J. Affect. Disord. 159: 56-61.
13. Murrough, J.W., A.M. Perez, S. Pillemer, et al. 2013. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry 74: 250-256.
14. Mathew, S.J., J.W. Murrough, M. aan het Rot, et al. 2010. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int. J. Neuropsychopharmacol. 13: 71-82.
15. Zarate, C.A., Jr., J.B. Singh, J.A. Quiroz, et al. 2006. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry 163: 153-155.
16. Smith, E.G., K.M. Deligiannidis, C.M. Ulbricht, et al. 2013. Antidepressant augmentation using the N-methyl-d-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 74: 966-973.
17. Sanacora, G., M.A. Smith, S. Pathak, et al. 2013. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 19: 978-985.
18. Sanacora, G., A. Khan, S. Atkinson, et al. 2014. Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequent response to antidepressants: primary results from a randomized, placebocontrolled study (PURSUIT). Presented at American Society of Clinical Psychiatry, Hollywood, FL.
19. Burch, R. 2012. A phase 2, randomized single blind, single intravenous dose of GLYX-12, an NMDA receptor glycine site functional partial agonist, in subjects with major depressive disorder with inadequate response to antidepressant medication. Presented at 51st Annual Meeting, American College of Neuropyschopharmacology, Hollywood, FL.
20. Huang, C.C., I.H. Wei, C.L. Huang, et al. 2013. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol. Psychiatry 74: 734-741.
21. Heresco-Levy, U., G. Gelfin, B. Bloch, et al. 2013. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int. J. Neuropsychopharmacol. 16: 501-506.
22. Schatzberg, A.F. 2014. A word to the wise about ketamine. Am. J. Psychiatry 171: 262-264.
23. Mehta, A.K., S. Halder, N. Khanna, et al. 2012. Antagonism of stimulation-produced analgesia by naloxone and N-methyl-D-aspartate: role of opioid and N-methyl-D-aspartate receptors. Hum. Exp. Toxicol. 31: 51-56.
24. Costa, A.C., T.R. Romero, D.F. Pacheco, et al. 2014. Participation of AT1 and Mas receptors in the modulation of inflammatory pain. Peptides 61: 17-22.
25. Yang, C. & K. Hashimoto . 2014. Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology 231: 2041-2042.
26. Li, N., B. Lee, R.J. Liu, et al. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
27. O'Reardon, J.P., H.B. Solvason, P.G. Janicak, et al. 2007. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol. Psychiatry 62: 1208-1216.
28. Carpenter, L.L., P.G. Janicak, S.T. Aaronson, et al. 2012. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress. Anxiety 29: 587-596.
29. Rabin, R.C. 2013. New approach to depression. The New York Times.
30. Mayberg, H.S., A.M. Lozano, V. Voon, et al. 2005. Deep brain stimulation for treatment-resistant depression. Neuron 45: 651-660.
31. Holtzheimer, P.E., M.E. Kelley, R.E. Gross, et al. 2012. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch. Gen. Psychiatry 69: 150-158.
32. Schlaepfer, T.E., B.H. Bewernick, S. Kayser, et al. Deep brain stimulation of the human reward system for major depression-rationale, outcomes and outlook. Neuropsychopharmacology 39: 1303-1314.
33. Wollmer, M.A., C. deBoer, N. Kalak, et al. 2012. Facing depression with botulinum toxin: a randomized controlled trial. J. Psychiatr. Res. 46: 574-581.
34. Finzi, E. & N.E. Rosenthal . 2014. Treatment of depression with onabotulinumtoxin A: a randomized, double-blind, placebo controlled trial. J. Psychiatr. Res. 52: 1-6.
35. Heller, A.S., R.C. Lapate, K.E. Mayer, et al. 2014. The face of negative affect: trial-by-trial corrugator responses to negative pictures are positively associated with amygdala and negatively associated with ventromedial prefrontal cortex activity. J. Cogn. Neurosci. 26: 2102-2110.
36. Schatzberg, A.F. 2014. Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression. World J. Biol. Psychiatry 16: 2-11.
37. Belanoff, J.K., B.H. Flores, M. Kalezhan, et al. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21: 516-521.
38. Flores, B.H., H. Kenna, J. Keller, et al. 2006. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31: 628-636.
39. DeBattista, C., J. Belanoff, S. Glass, et al. 2006. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol. Psychiatry 60: 1343-1349.
40. Blasey, C.M., T.S. Block, J.K. Belanoff, et al. 2011. Efficacy and safety of mifepristone for the treatment of psychotic depression. J. Clin. Psychopharmacol. 31: 436-440.
41. Watson, S., P. Gallagher, R.J. Porter, et al. 2012. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol. Psychiatry 72: 943-949.
42. Buckley, T.M. & A.F. Schatzberg . 2010. A pilot study of the phase angle between cortisol and melatonin in major depression - a potential biomarker? J. Psychiatr. Res. 44: 69-74.
43. Zajecka, J., A.F. Schatzberg, S. Stahl, et al. 2010. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 30: 135-144.
44. Koesters, M., G. Guaiana, A. Cipriani, et al. 2013. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br. J. Psychiatry 203: 179-187.